About Prosetta


Using cell free protein synthesis to recreate pivotal cellular regulatory events, San Francisco’s Prosetta Biosciences, Inc. has discovered a completely new class of targets (called “assembly machines”) that are controlled allosterically and are highly druggable. Our proprietary technology platform has identified a collection of fewer than 400 small, chemically tractable molecules (the "Prosetta Hit-Finder Collection") that contains active compounds relevant to a broad range of human diseases. We are now moving select compounds against important viral diseases towards the clinic while also working with commercial and not-for-profit partners to advance other compounds in the fields of oncology, neurodegenerative diseases, and infectious diseases.